ARIA Stock – Ariad Shares Pop on Potential Buyout Rumors

Its stock plunged in October after a drug trial was stopped

   

A report that Ariad Pharmaceuticals Inc. (ARIA) has been approached by potential buyers sent ARIA stock up more than 8% in Thursday pre-market trading.

Ariad ARIA Stock   Ariad Shares Pop on Potential Buyout RumorsAccording to the Daily Mail, Ariad has received “friendly approaches” from a minimum of three major pharmaceutical makers. Interested parties are said to include Eli Lilly (LLY), GlaxoSmith Kline (GSK) and Shire (SHPG).

JohnsonJohnsonLogo e1282585796958 ARIA Stock   Ariad Shares Pop on Potential Buyout Rumors
JNJ Stock – Johnson & Johnson Beats Profit Estimates on Strong Drug Sales

ARIA stock had traded over $20 a share in September, but ARIA stock plunged in October after the U.S. Food and Drug Administration halted a trial of its anti-cancer treatment, Iclusig, after some patients developed blood clots.

The buyers are reportedly willing to pay as much as $20 a share for ARIA stock. On Wednesday, ARIA stock closed at $6.71 a share.

In December, Ariad announced that the FDA would allow Inclusig to return to the market under new marketing restrictions, sending ARIA stock somewhat higher.


Article printed from InvestorPlace Media, http://investorplace.com/2014/01/aria-stock-ariad-shares-pop-potential-buyout-rumors/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.